Thelma S. Angeles - Concepedia

Author

Thelma S. Angeles

Also Known As

Angeles, T.S., Angeles, Thelma S., T Angeles, T. S. ANGELES, T.S. Angeles, Thelma Angeles, Thelma S Angeles, Thelma S. Angeles, Theresa Angeles

105

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

Brandywine Photonics (United States)Avalon Pharma (United States)Kyowa Kirin (Japan)Teva Pharmaceuticals (United States)Worldwide Clinical Trials (United States)

About

Thelma S. Angeles is an author at Brandywine Photonics (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	38	1.5K
2	Natural Sciences	15	17	602
3	Biochemistry	14	17	508
4	Engineering	2	2	58
5	Biomedical Engineering	1	1	39

Thelma S. Angeles

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Motoneuron Apoptosis Is Blocked by CEP-1347 (KT 7515), a Novel Inhibitor of the JNK Signaling Pathway Anna C. Maroney, Marcie A. Glicksman, Alie N. Basma, Journal of Neuroscience	1998	292
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders Elizabeth O. Hexner, Cynthia Serdikoff, Mahfuza Jan, Blood	2007	251
CEP-1347 (KT7515), a Semisynthetic Inhibitor of the Mixed Lineage Kinase Family Anna C. Maroney, James P. Finn, Thomas J. Connors, Journal of Biological Chemistry	2001	204
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Daniel J. George, Craig A. Dionne, Jacques Jani, PubMed UrologyAndrogen AblationChemoprevention StrategyGenitourinary CancerEndocrine-related Cancer	1999	126
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Bruce Ruggeri, J. B. Singh, Diane E. Gingrich, PubMed Chemoprevention StrategyAntitumor EfficacyTumor BiologyActive Pan InhibitorAngiogenesis	2003	124
Neurotrophic 3,9-Bis[(alkylthio)methyl]- and -Bis(alkoxymethyl)-K-252a Derivatives Masami Kaneko, Yutaka Saito, Hiromitsu Saito, Journal of Medicinal Chemistry	1997	119
Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells Weihua Wan, Mark S. Albom, Lihui Lü, Blood	2005	105
Structure-guided identification of novel VEGFR-2 kinase inhibitors via solution phase parallel synthesis Rabindranath Tripathy, Alyssa Reiboldt, Patricia A. Messina, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryDrug TargetMedicineNatural SciencesReceptor Tyrosine Kinase	2006	104
Mixed lineage kinase activity of indolocarbazole analogues Chikara Murakata, Masami Kaneko, George Gessner, Bioorganic & Medicinal Chemistry Letters Receptor Tyrosine KinaseIndolocarbazole AnaloguesDrug DiscoverySystems Biology	2002	93
1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors Rabindranath Tripathy, Arup K. Ghose, J. B. Singh, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryMedicineRational Drug DesignPharmacotherapyDrug Development	2006	89

Page 1